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Abstract: Glucocorticoids are steroid hormones with key roles in the regulation of many physiological
systems including energy homeostasis and immunity. However, chronic glucocorticoid excess,
highlighted in Cushing’s syndrome, is established as being associated with increased cardiovascular
disease (CVD) risk. Atherosclerosis is the major cause of CVD, leading to complications including
coronary artery disease, myocardial infarction and heart failure. While the associations between
glucocorticoid excess and increased prevalence of these complications are well established, the
mechanisms underlying the role of glucocorticoids in development of atheroma are unclear. This
review aims to better understand the importance of glucocorticoids in atherosclerosis and to dissect
their cell-specific effects on key processes (e.g., contractility, remodelling and lesion development).
Clinical and pre-clinical studies have shown both athero-protective and pro-atherogenic responses to
glucocorticoids, effects dependent upon their multifactorial actions. Evidence indicates regulation
of glucocorticoid bioavailability at the vasculature is complex, with local delivery, pre-receptor
metabolism, and receptor expression contributing to responses linked to vascular remodelling
and inflammation. Further investigations are required to clarify the mechanisms through which
endogenous, local glucocorticoid action and systemic glucocorticoid treatment promote/inhibit
atherosclerosis. This will provide greater insights into the potential benefit of glucocorticoid targeted
approaches in the treatment of cardiovascular disease.
Keywords: glucocorticoids; atherosclerosis; inflammation; cardiovascular diseases; glucocorticoid
receptor; lipids
1. Introduction
Glucocorticoids are steroid hormones with an essential role in the regulation of numer-
ous physiological processes, including energy utilisation, immune response, blood pressure,
mood/memory, and stress responses [1]. Their secretion into the circulation occurs in a
pulsatile, circadian manner with peak levels prior to waking, and a nadir during the early
stages of sleep. Additionally, there is also evidence of longer infradian rhythms of cortisol
excretion suggesting more complex control than just circadian rhythmicity, which may add
further complication to accurate measurement of exposure to cortisol [2]. Glucocorticoids
are synthesised from cholesterol in the cortical layer of the adrenal gland, specifically
the zona fasciculata, and are released in response to stimulation by adrenocorticotropic
hormone (ACTH) secreted from the anterior pituitary gland. This release is regulated by
feedback control of the hypothalamic pituitary adrenal (HPA) axis. In humans, the primary
glucocorticoid is cortisol although they also produce corticosterone, whereas in rodents,
which provide primary pre-clinical models for disease, the lack of adrenal CYP17A1 means
corticosterone is the sole glucocorticoid [3].
In the circulation, the bioavailability of glucocorticoids is regulated by plasma binding
proteins—primarily corticosteroid-binding globulin (CBG), but also albumin [4]. Under
normal physiological conditions, 80–90% of glucocorticoids are bound to CBG and 10–15%
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are bound to albumin, while 2–10% remain unbound or “free”. Only the free fraction is able
to diffuse across cell membranes into cells and exert biological activity [5,6]. Glucocorticoids
exert the majority of their actions through genomic routes via either the ubiquitously
expressed glucocorticoid receptor (GR), or the tissue-specific mineralocorticoid receptor
(MR); binding MR with higher affinity [7–9].
Glucocorticoids have important roles in physiology and are key in the maintenance of
cardiovascular health. This review will focus on the ability of glucocorticoids to regulate
atherosclerosis, both in terms of driving the pathogenesis of the disease (pro-atherogenic),
and as a potential therapeutic option to limit disease severity (athero-protective). Here
we will outline the historical literature and explore the more recent evidence underlying
how glucocorticoids influence the development of atheromatous plaques, in particular
dissecting the cell-specific mechanisms regulating glucocorticoid action in this disease
setting.
2. Glucocorticoids and Cardiovascular Risk: More Than an Association?
The ability of glucocorticoids to regulate numerous key physiological processes, in par-
ticular the body’s immune response and fuel metabolism, mean they play an important role
in the maintenance of cardiovascular health. However, these essential, adaptive responses
can become maladaptive upon chronic exposure to elevated levels of glucocorticoids
(Table 1). Indeed, there is a well-established correlation between chronic glucocorticoid
excess and increased cardiovascular disease (CVD) risk, notably the development of key
risk factors including obesity, diabetes, hypertension, and dyslipidaemia [9,10].
Table 1. Glucocorticoid action in cardiovascular health: when adaptive becomes maladaptive.
Acute, Adaptive Physiological Roles Chronic, Maladaptive Effects Pathological Outcomes References
Regulation of glucose homeostasis Hyperglycaemia Diabetes mellitus [11]Insulin resistance
Maintenance of energy homeostasis Visceral adiposity Obesity [12]General weight gain





Regulation of lipid metabolism Elevated cholesterol Dyslipidaemia [14]Elevated triglycerides
Heart development and function BradycardiaCardiac hypertrophy Heart failure [13]
Regulation of clotting factors and fibrinogen Hypercoagulability Thrombosis [15,16]
Glucocorticoids act in an acute manner on multiple physiological systems to restore homeostasis. Chronic exposure to excess glucocorticoid
turns adaptive responses into maladaptive outcomes, resulting in pathologies linked to the development of cardiovascular disease.
The most striking demonstration of the cardiovascular consequences of glucocorticoid
excess remains that highlighted in the clinical presentation of Cushing’s syndrome [17].
Individuals with this condition have excess endogenous cortisol production, typically
resulting from either pituitary or adrenal tumours, and present multiple symptoms in-
cluding visceral obesity, insulin resistance and dyslipidaemia—all CVD risk factors [17].
Moreover, analysis has demonstrated that Cushing’s patients have an increased risk of
cardiovascular events such as coronary artery disease, myocardial infarction, stroke and
heart failure [18,19].
Whilst cases of Cushing’s are extremely rare, affecting between 40 and 70 people
out of every million [20], the link between glucocorticoid excess and cardiovascular risk
has been identified in other scenarios. Sub-clinical hypercortisolism (also referred to as
“subclinical Cushing’s syndrome”, “pre-clinical Cushing’s syndrome”, or “sub-clinical
autonomous glucocorticoid hypersecretion”) is an imperfectly defined condition indicated
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in patients exhibiting mild alteration in cortisol secretion without the symptoms of Cush-
ing’s syndrome [21,22]. It is usually associated with adrenocortical incidetalomas detected
during imaging for conditions unrelated to the adrenal gland. Clinical investigations have
associated chronic exposure to “sub-clinical” hypercortisolism with a number of compli-
cations (including excess weight/obesity, hypertension, and diabetes mellitus) that are
risk factors for CVD [22,23]. Indeed, there is some evidence of increased cardiovascular
events and mortality in these patients, indicating a possible benefit from medical interven-
tion or adrenalectomy [24]. This is important as adrenal incidentalomas are considerably
more common than Cushing’s syndrome (possibly present in 4–7% of adults) [25], and
the prevalence of sub-clinical hypercortisolism in these patients has been estimated as
0.2–2.0% [23].
A further link between glucocorticoid excess and the development of cardiovascular
disease has been suggested in patients with metabolic syndrome; a condition associated
with increased cardiovascular risk [26]. The similarity between the features of metabolic
syndrome (a combination of at least three symptoms out of central obesity, hypertension,
hyperglycaemia, hypertriglyceridaemia, and low serum high-density lipoprotein) and
Cushing’s syndrome, has prompted the suggestion that the former represents a “low cor-
tisol”, or “tissue-specific” form of Cushing’s syndrome [27]. This proposal is based on
an improved understanding of the role of glucocorticoid-metabolising enzymes (specif-
ically the 11β-hydroxysteroid dehydrogenases (11β-HSDs)) in regulating activation of
corticosteroid receptors in a tissue-specific manner: raising the possibility of tissue-specific
glucocorticoid excess through aberrant expression of the 11β-HSD isozymes (e.g., in the
liver [28] or central adipose tissue [29]) without elevated circulating levels of the steroid.
This has led to the investigation of pharmacological targeting of 11β-HSDs for treatment of
metabolic disease.
In addition to the evidence obtained from exposure to elevated endogenous gluco-
corticoids, the widespread therapeutic use of glucocorticoids to treat inflammatory and
autoimmune conditions has also provided supporting evidence for their association with
CVD. While effective in alleviating symptoms of asthma, systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA) [30], glucocorticoids do not treat the underlying cause
of these diseases, and in many cases patients remain on long-term glucocorticoid treatment
to effectively manage their condition. Unless carefully managed, this chronic exposure to
supraphysiological doses of glucocorticoids can result in iatrogenic Cushing’s syndrome.
Several studies have highlighted that patients administered high dose glucocorticoids have
an increased risk of CVD (as reviewed by [31]). A recent analysis of a UK population-based
cohort demonstrated an increased risk of cardiovascular events across six different im-
mune pathologies in which patients were being treated with prednisolone [32]. This study
demonstrated a dose-dependent effect of prednisolone associated with an increase in the
prevalence of cardiovascular events such as acute myocardial infarction and peripheral
arterial disease. While this supports previous studies in which similar dose-dependent
effects of glucocorticoid treatment were observed to increase the risk of cardiovascular
events [33,34], this work highlighted that even long term low dose glucocorticoid treatment,
previously considered “safe”, resulted in a doubling of overall CVD risk [32].
Together, the evidence for an association between increased exposure to glucocor-
ticoids and increased CVD risk is clear, yet the question of causality remains. Using
Mendelian randomisation and data collected across 17 studies of European ancestry, a re-
cent study tested whether genetically elevated cortisol in the general population is causally
associated with a number of cardiovascular risk factors [35]. Importantly, the authors
demonstrate that increased cortisol causally increases the risk of ischaemic heart disease
and myocardial infarction. However, as alluded to by the authors, their measures of morn-
ing plasma cortisol are likely poor surrogates for overall tissue exposure. Indeed, over
the years several intricate molecular mechanisms have been identified that regulate the
cellular exposure to glucocorticoids. To further assess the impact of glucocorticoids on
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atherosclerosis per se, a greater knowledge of glucocorticoid action at a cell-specific level is
required, in parallel with more robust assessments of glucocorticoid phenotypes.
3. Atherosclerosis: A Complex, Multi-Cellular Pathophysiology
Atherosclerosis is a progressive inflammatory disease, characterised by a narrowing of
the arteries due to vascular remodelling and formation of atheromatous plaques (Figure 1).
The clinical manifestation of atherosclerosis is dependent on the site of plaque formation
and the organ affected by impaired blood supply. The development of atherosclerosis in
the coronary arteries (coronary heart disease) can cause angina and myocardial infarction,
whereas presentation in the brain and cerebral circulation (cerebrovascular disease) can
result in a stroke.
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circulating LDL-cholesterol infiltrates the intimal layer and becomes oxidised by free radicals into oxidised LDL (oxLDL),
triggering an inflammatory cascade in which immune cells (including monocytes and neutrophils) are recruited from the
circulation by attachment t adhesion olecules (VCAM-1 and ICAM-1) on the surface f the endothelium. Infiltrated
onocytes differentiate into pro-inflamma ory macrophages and ingest oxLDL, f rming foam cells. Sm oth mus e cells
ig ate from the medial layer and differentiate to form fibrous cap containing collagen and elastin. Proteases including
matrix metalloproteinases (MMPs) and neutrophil elastase (NE) are released from immune cells, resulting in degradation of
the extracellular matrix, facilitating vascular remodelling and enhancing the pro-inflammatory mileu. The accumulation of
foam cells, apoptotic/necrotic cells and migrated smooth muscle cells forms a necrotic core, which upon rupture is highly
thrombotic.
In line with our current understan ing from pre-clinical models, there are two key
events in atherogenesis: endothelial cell damage a d vascu ar remodelling. In particular,
the ecruitment and activati n of irculating immune cells, lipoprotein ret ntion, and the
migration and proliferation of vascular smooth muscle cells (vSMCs) are viewed as critical
cellular responses. Research has established that initial intimal thickening of arteries is
physiological, developing silently throughout an individual’s lifetime, and is evident in
young children and even babies less than a year old [36]. However, this adaptive intimal
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thickening can progress into maladaptive remodelling upon exposure to high circulating
levels of cholesterol, specifically low-density lipoproteins (LDL), alongside endothelial cell
damage as proposed by the response-to-injury hypothesis [37]. Damage to the endothelium
causes increased permeability, allowing LDL to migrate into the sub-endothelial space
of the intimal layer and become oxidised (oxLDL) [38]. This accumulation of lipoprotein
triggers a cascade of inflammatory cell influx into the intima of the vascular wall. In
particular, monocytes are recruited to the sub-endothelial layer by attachment to adhesion
molecules including vascular cell adhesion molecule (VCAM-1) and intercellular adhesion
molecule (ICAM-1), expressed on the activated endothelial cells following endothelial
cell damage [39]. However, there is also evidence of neutrophil infiltration following
endothelial cell damage, with studies in pre-clinical models indicating that their levels
peak at the early stage of atherosclerosis and fall to almost undetectable levels in devel-
oped plaques [40,41]. While other immune cells are also implicated in the development
of atherosclerosis, including dendritic cells, mast cells and lymphocytes [42], monocyte
recruitment and subsequent differentiation into macrophages within the intima reflects
the central role of monocytes/macrophages in plaque formation. Macrophage activation
within the vasculature results in the ingestion of local oxLDL, and the subsequent forma-
tion of foam cells. The accumulation of these foam cells is a central part of the vascular
remodelling in atherosclerosis, and results in a “fatty streak” which can either stabilise,
regress or progress into an atherosclerotic plaque.
The proliferation and migration of vSMCs from the media to the intima forms another
significant component of vascular remodelling. Under the pro-inflammatory environment,
vSMCs undergo a phenotypic switch in which they lose their contractile phenotype, re-
leasing growth factors and matrix metalloproteases (MMPs), and gain a more macrophage
and foam cell-like phenotype [38,43]. As these foam cells undergo apoptosis or necrosis,
the aggregation of inflammatory cells and cytokines, macrophage-like vSMCs, and dying
foam cells, form a necrotic core between the intimal and medial layers causing further
plaque instability and inflammation. At this stage, there can be further pathological intimal
thickening, and vascular dysfunction due to loss of contractility of the vascular smooth
muscle and impaired endothelium-dependent relaxation. A fibrotic cap composed of
connective tissue forms, which is postulated to be a protective remodelling mechanism to
prevent leakage of the pro-thrombotic material into the circulation [38].
A major aspect of vascular remodelling is the degradation of extracellular matrix
(ECM), which occurs as a consequence of protease action. Neutrophil elastase (NE) and
MMPs, released from activated neutrophils, macrophages, endothelial cells and vSMCs are
key proteases that promote the breakdown of ECM by degrading structural proteins such
as collagen and elastin [44,45]. The result of this is structural damage to the vasculature,
contributing to plaque rupture and lack of contractility. Of particular interest is a newly
identified role for NE in atherosclerosis. The expression of NE is increased both in human
plaques and in plaques from murine models of atherosclerosis [46,47], but recent studies
have explored a causative role for this protease, demonstrating a pathogenic role in foam
cell formation through modulation of cholesterol efflux [46].
In humans, most plaques are stable and remain asymptomatic; however, plaques can
rupture resulting in thrombosis and occlusion of arteries. The “stabilisation” of plaques is
regarded as any change in the composition in which reduces the plaques vulnerability to
rupture or erode. Therefore, identifying characteristics of these “unstable” plaques is crucial.
Indeed, stable plaques have thick protective fibrous caps with small necrotic cores with
less macrophage infiltration [48]. The question of plaque vulnerability underlines crucial
species-specific differences in atherosclerosis and highlights a limitation of pre-clinical
research into atherosclerosis. For example, plaques in murine models of atherosclerosis
such as ApoE−/− mice can have features of vulnerability, but death caused by plaque
rupture is not evident [49].
Additionally, it is important to recognise that approximately 20% of deaths in acute
coronary syndrome (ACS) patients can be caused by superficial plaque erosion, which has a
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distinct mechanism from plaque rupture [50]. Typically, eroded plaques have fewer inflam-
matory cells, and lack the lipid rich necrotic core associated with vulnerable plaques [50].
The different plaque types produce different thrombi, with eroded plaques producing
white thrombus with high platelet content whereas ruptured plaques produce red throm-
bus with a high lipid and fibrin content [51]. The events that determine whether a plaque
erodes, or ruptures are still unclear, although research remains predominantly focused on
understanding plaque rupture. Intriguingly, eroded plaques are more frequently seen in
younger patients and females, compared to plaque rupture which is commonly seen in
older patients and those with CVD risk factors [51]. These differences in patient epidemi-
ology may yield insight into the underlying mechanisms which determine the fate of the
plaques.
4. Are Glucocorticoids Athero-Protective or Drivers of Lesion Development?
The cumulative evidence gathered over the past 20 years highlighting increased
atherosclerosis in Cushing’s patients suggests that glucocorticoids may be pathophysiolog-
ical drivers of plaque development. Individuals with Cushing’s exhibit higher circulating
LDL levels, a thickened intimal-medial layer, and a more narrowed lumen in the carotid
artery compared to age- and sex-matched non-Cushing’s individuals [52]. A more recent
meta-analysis investigating atherosclerosis in Cushing’s also concluded that individuals
with Cushing’s Syndrome have a thickened intimal-medial layer and larger plaques in
their carotid artery, along with impaired vasodilation compared to control non-Cushing’s
individuals [53]. Notably, this vascular remodelling occurs independent of several cardio-
vascular/atherosclerosis risk factors including smoking, body mass index, blood pressure,
glucose levels and lipid levels. Indeed, when compared with healthy and hypertensive
individuals, patients with Cushing’s show increased carotid intima-media thickness and a
higher prevalence of plaques (26% vs. 0 and 16%, respectively) [54]. Cushing’s patients
also demonstrated increased ankle-brachial index (ABI) compared to controls, a clinical
marker of peripheral vascular disease (PVD) [54]. Strikingly, this evidence of increased
atheroma remains beyond the remission of Cushing’s when compared to non-Cushing’s in-
dividuals, indicating irreversible consequences of systemic changes [19,55]. The increased
risk of CVD in these patients, during and beyond remission, highlights the importance of
understanding the mechanisms underlying the role of glucocorticoids in atherosclerosis.
The lesion burden of lower limb PVD patients is greater in individuals that have
had long term (>5 years) glucocorticoid treatment compared to individuals that have
plaques but no previous exposure to exogenous glucocorticoid [56]. In particular, SLE
and RA patients have accelerated atherosclerosis which is thought to be due to their
glucocorticoid treatment [57,58]. However, it is important to recognise that individuals
receiving glucocorticoid therapy often have significant underlying inflammatory conditions.
Indeed, independent of glucocorticoid therapy, the increased cardiovascular risk of these
SLE and RA patients is thought to be attributed to underlying systemic inflammation,
endothelial cell dysfunction and vascular remodelling [59–61]. While these studies have
demonstrated a positive correlation between glucocorticoids and plaque development, a
causal relationship remains an area of active study in pre-clinical models.
Although chronic, supraphysiological exposure to glucocorticoids increases the risk
and burden of atherosclerosis in humans, the earliest evidence of glucocorticoid action in
pre-clinical models indicated a protective role. In cholesterol-fed rabbits, co-administration
of “low dose” dexamethasone (0.125 mg/day) protected against further progression of
atherosclerosis, with reduced plaque development, macrophage recruitment and subse-
quent foam cell formation [62,63]. In mice with atherosclerosis, both acute (5 weeks) and
chronic (17 weeks) high dose corticosterone administration (50 mg/mL in drinking wa-
ter) during development of atherosclerosis decreased lesion size compared with vehicle
controls [64]. Notably, chronic administration of corticosterone was accompanied by a
marked decrease of macrophage content in lesions (56% vs. 27% in acute treatment). This
suggests long-term glucocorticoid exposure over the course of atheroma development
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can be athero-protective by reducing monocyte/macrophage recruitment and foam cell
formation. Indeed, this is supported by a recent study demonstrating the direct ability of
prednisone/prednisolone to reduce cholesterol accumulation in macrophages [65].
In contrast, a number of pre-clinical studies employing manipulations in endogenous
glucocorticoid levels, often subtle in comparison to the pharmacological administration
seen above, have demonstrated pro-atherogenic effects of glucocorticoids. In ApoE−/−
mice, a chronic increase in endogenous corticosterone levels in response to repeated stress-
ful stimuli increased the prevalence of lesions compared to unstressed mice [66]. Similarly,
genetic manipulation of endogenous corticosterone in mouse models of atherosclerosis
supports a pro-atherogenic role. Mice lacking the glucocorticoid inactivating enzyme 11β-
HSD2 display accelerated atherosclerosis development when crossed with ApoE−/− mice,
compared to controls [67], while mice lacking the enzyme responsible for generating active
corticosterone from inactive 11-dehydro corticosterone in tissues, namely 11β-HSD1, have
reduced plaque size and severity on an ApoE−/− background compared to controls [68].
Intriguingly, and in contrast to the effects of exogenous glucocorticoid administration, the
cellular mechanism underlying the reduction in atherosclerosis in these models has been
attributed to altered cholesterol flux in macrophages within lesions, resulting in increased
foam cell formation [68,69].
From an overview standpoint there appears compelling evidence for glucocorticoids
to act in both an adverse and beneficial manner in the context of atherosclerosis. However,
the question of whether glucocorticoids can be viewed as drivers of atherosclerosis or
anti-atherogenic is more likely too simplistic an approach. Rather, it is becoming clear that
the key to understanding this apparent paradox requires a multifactorial approach, and lies
in identifying the crucial cellular targets of glucocorticoids in the vasculature compared to
the broad targets resulting from systemic administration, and in parallel understanding
the mechanisms that such cells utilise to regulate their response to glucocorticoids.
5. Glucocorticoid-Mediated Regulation of Endothelial Cell Dysfunction
The importance of glucocorticoids in maintaining vascular reactivity is well estab-
lished, and they are vital for regulation of blood pressure and blood flow [70,71]. However,
these crucial physiological effects can become adverse in the long-term, as seen in the
pathogenesis of Cushing’s-induced hypertension [72]. This evidence implies an important
role for glucocorticoids in contributing to endothelial cell dysfunction.
Glucocorticoids can influence vascular reactivity through modulating either vasocon-
striction or vasodilation (Figure 2). Endothelin-1 (ET-1) and angiotensin-II (AngII) are two
well-studied vasoconstrictors regulated by glucocorticoids. ET-1 acts on ETA and ETB recep-
tors in a paracrine manner on vSMCs to cause contraction, and in an autocrine manner on
endothelial cells to cause relaxation [73]. In human atherosclerosis, circulating ET-1 levels
are increased, in parallel with increased expression of ET-1 receptor subtypes in atheroscle-
rotic lesions [74,75]. Early in vitro studies in both rat and rabbit vSMCs demonstrated
the ability of glucocorticoids to increase ET-1 mediated contractility through increased
ET-1 production [76,77], an effect shown to be GR-dependent [78]. The production of
AngII is controlled through the action of angiotensin converting enzyme (ACE), converting
AngI to the active vasoconstrictor AngII. In response to low blood pressure, endothelial
cell production of ACE enhances local generation of AngII, causing vasoconstriction and
restoring normal blood pressure [79]. However, excessive ACE-mediated AngII production
can result in inappropriate vasoconstriction, contributing to endothelial cell dysfunction.
Fishel et al. demonstrated that exposure of cultured rat vSMCs to dexamethasone increased
both ACE mRNA and activity [80]. These findings were subsequently extended to human
vSMCs and expanded upon to show that induction of ACE led to increased activation of
AngII-mediated intracellular signalling via the phospholipase C pathway, stimulating in-
tracellular Ca2+-mediated contraction [81]. Moreover, glucocorticoids can further enhance
vasoconstriction by inducing AngII type I (AT I) receptors in vSMCs, enhancing AngII
signalling [82].
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Figure 2. Glucocorticoid-mediated effects on vascular contractility. (A) Cross-section of an artery
demonstrating comparative differences during normal conditions, under vasoconstriction, and
under vasodilation. (B) Glucocorticoids can both inhibit and promote vasodilation in endothelial
cells. Glucocorticoids can increase reactive oxygen species (ROS), which act to reduce itric oxide
(NO) availability, a key driver of vasodilation. Glucocorticoid a also inhibit NO production by
redu ing end thelial nitric oxide synthase (eNOS). H wever, there is conflicting data indicating that,
under certain conditions (e.g., high dose), glucocorticoids can induce eNOS, driving NO-mediated
vasodilation. (C) Glucocorticoids can promote vascular contractility in smooth muscle cells through
increasing production and activity of the vasoconstrictors endothelin-1 (ET-1) and Angiotensin II
(AngII), the latter through increased expression of angiotensin-converting enzyme (ACE) and the
Angiotensin II type 1 receptor (AT-1). ET-R—Endothelin-1 receptors; AngI—angiotensin I.
Glucocorticoids can also regulate vascular tone through modulation of vasodilation.
In particular, they can inhibit the synthesis and release of the vasodilators nitric oxide
(NO) and prostacyclin (PGI2) from endothelial cells [83]. The maintenance of NO is key for
physiological function, with imbalances in NO contributing to both atherosclerosis and
hypertension. Dexamethasone has been shown to promote reactive oxygen species (ROS)
overproduction in human endothelial cells through action on the mitochondrial electron
transport chain, NAD(P)H oxidase and xanthine oxidase [84], reducing the bioavailability
of NO and causing oxidative stress, contributing to endothelial cell damage in the vascula-
ture. Moreover, acute in vivo exposure to dexamethasone in rats blocks the synthesis of NO
in the endothelium by inhibiting endothelial nitric oxide synthase (eNOS) [85], which is
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proposed to be a result of transcriptional repression and increased mRNA degradation [70].
Taken together, glucocorticoids can directly induce endothelial cell dysfunction through
hypercontractility and inhibition of vasodilation which may contribute to the initiation
of atherosclerosis. On the other hand, there is contrasting evidence demonstrating that
high dose glucocorticoids may promote the synthesis of vasodilators. Exposure to dexam-
ethasone can activate eNOS in human endothelial cells through non-genomic mechanisms,
reducing vascular inflammation in a mouse model of vascular injury [86]. In a murine
model of myocardial infarction, dexamethasone increased basal eNOS activity by 39% [86].
While species- and model-specific differences may play a role in these contrasting results.
The higher concentration of dexamethasone used in the murine study compared to the rat
study [85], suggests dose-dependent effects, with acute low dose exposure to glucocorti-
coids inhibiting vasodilator production, whereas high dose glucocorticoid exposure may
have vasodilatory effects.
6. Effects of Glucocorticoids on Vascular Remodelling
As with endothelial cell dysfunction, glucocorticoids have been shown to have con-
trasting athero-protective and pro-atherogenic effects on cells involved in vascular re-
modelling during lesion formation (Figure 3). Glucocorticoid actions on endothelial
cells are widely accepted, downregulating their expression of adhesion molecules in-
cluding ICAM-1, VCAM-1 and E-selectin, and thus reducing recruitment of monocytes
and neutrophils [87–89]. Moreover, glucocorticoids inhibit endothelial cell production
of pro-inflammatory cytokines including IL-6, CXCL8 (IL-8) and CCL2 (MCP-1) [90,91].
Together, these actions are likely beneficial in atherosclerosis by dampening the immune
response.
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Figure 3. Summary of cell-specific effects of glucocorticoids during atherosclerotic plaque develop-
ment. Evidence indicates that glucocorticoids are capable of exerting both athero-protective and pro-
atherogenic (pro-athero) effects in several crucial cell types. In endothelial cells, glucocorticoid action
is athero-protective. However, in both smooth muscle cells and macrophages, evidence exists of both
pro-athero and athero-protective effects. oxLDL—oxidised LDL; MMP—matrix metalloproteinases.
However, evidence indicates that glucocorticoid-mediated responses in both vSMCs
and macrophages may depend on the experimental model, as well as the level of glucocor-
ticoid exposure. Glucocorticoids can have potentially atheroprotective effects on vSMCs by
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inhibiting their migration and proliferation, key events underlying intimal thickening and
vascular remodelling. Initial studies in a rabbit carotid collar vascular injury model found
that dexamethasone administration 24 h prior to collar-induced vascular injury inhibited
intimal thickening, a result of glucocorticoid-mediated inhibition of vSMC migration and
proliferation [92]. In rats, dexamethasone has been demonstrated to suppress aortic SMC
proliferation by inhibiting phosphorylation of Rb, a checkpoint for the G1 phase of mito-
sis [93,94], and through inhibition of PDGF-induced migration, mediated by upregulation
of PGC-1α expression [95]. In human vSMCs isolated from atherosclerotic arteries, several
synthetic glucocorticoids (dexamethasone, hydrocortisone, prednisolone) show clear in-
hibitory effects on vSMC migration in vitro [96]. In contrast, the ability of glucocorticoids
to induce ET-1 production in vSMCs is known to promote vSMC migration [97,98].
During atherogenesis, vSMC migration is dependent upon MMP-mediated break-
down of the ECM to facilitate movement. Specifically, MMP-2 and MMP-9 are increased
after vascular injury. Dexamethasone treatment inhibits MMP-2 activity and migration in
rat vSMCs; however, this effect was not observed in human aortic vSMCs [99]. Additionally,
cortisol inhibited MMP-2 secretion in a human macrophage cell line [100]. These differing
outcomes may indicate species-specific responses of vSMC to glucocorticoids but may also
be a result of the experimental paradigm; in their respective studies dexamethasone and
cortisol were administered for 30 min vs. 24 h. The individual contribution of each of
these actions to atherosclerotic plaque development is difficult to dissect. However, it is
important to consider that, in the context of vSMC migration and proliferation, potential
beneficial effects resulting from reduced migration must also be considered in light of
plaque stability, since vSMC are major components of the “protective” fibrotic cap.
Aside from an inhibitory role on monocyte recruitment, there is evidence of multiple,
often contrasting, effects of glucocorticoid on macrophages during atherosclerotic plaque
development. In rabbits, systemic dexamethasone treatment reduced macrophage accumu-
lation in the intimal and medial layers of the femoral artery, suggesting a protective role of
glucocorticoids in vascular remodelling [101]. Indeed, this would support established liter-
ature demonstrating the ability of glucocorticoids to inhibit the release of pro-inflammatory
mediators such as TNF-α and IL-12 from macrophages [102], thus dampening their pro-
inflammatory response. However, targeted delivery of prednisolone to macrophages via
liposomes throughout disease progression in LDLR−/− mice accelerated atherosclero-
sis, with increased macrophage content and larger necrotic cores [103]. This paradoxical
pro-atherogenic effect was believed to result from glucocorticoid-induced macrophage lipo-
toxicity. In line with a lack of a protective effect of glucocorticoids on atherosclerosis when
targeted directly to macrophages, a similar study in humans delivering prednisolone in
liposomes found that while these liposomes accumulated in macrophages of atherosclerotic
femoral lesions, they showed none of the expected anti-inflammatory effects [104]. Instead,
further evidence supports a role for glucocorticoids in driving atherogenesis by promoting
macrophage lipotoxicity. Specifically, glucocorticoids have been shown to stimulate choles-
terol esterification and suppress HDL efflux both in human vSMCs and in macrophages
in a GR-dependent manner [105,106]. However, these studies explored glucocorticoid
influence on intracellular cholesterol trafficking. A recent study has demonstrated the
ability of glucocorticoids to reduce oxLDL uptake in human macrophages by suppressing
expression of genes involved in influx, potentially limiting progression of atherosclerosis
by preventing accumulation of lipids [107].
In summary, glucocorticoids can play a role in endothelial cell dysfunction and vas-
cular remodelling, with the potential to induce effects that either drive or oppose the
development of atherosclerosis (illustrated in Table 2). To further understand these conflict-
ing effects of glucocorticoids at the vascular level it is important to understand control of
local availability of glucocorticoid in specific tissues.
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Table 2. Actions of glucocorticoids in the vessel wall that may inhibit or enhance atherosclerotic lesion formation.
Potential Impact Target Effect Reference
Pro-Atherosclerotic
Endothelium ↓ generation of EDRFs [83]
Endothelium ↑ ROS generation [84]
Endothelium ↓ eNOS [85]
vSMC ↑ vasoconstrictor (ET-1) generation [78]
vSMC ↑ vasoconstrictor (AngII) generation [80,81]
vSMC ↑ AT-1 receptor expression [82]
vSMC ↑ accumulation of cholesterol esters [106]
Macrophages ↑ lipotoxicity [104]
Macrophages ↑ accumulation of cholesterol esters [105]
Anti-Atherosclerotic
Endothelium ↑ eNOS (non-genomic) [86]
Endothelium ↓ adhesion molecule expression [87–89]
Endothelium ↓ expression of pro-inflammatory cytokines [90,91]
Macrophages ↓ accumulation [101]
Macrophages ↓ expression of pro-inflammatory cytokines [102]
Macrophages ↓ oxLDL uptake and cholesterol efflux [107]
Unclear vSMCs ↓ proliferation and migration [92–96,99]
Glucocorticoids can exert effects on cells involved in the formation of atherosclerotic lesions that may be predicted to either promote or
inhibit lesion formation. The impacts of some glucocorticoid-mediated actions are more difficult to predict as they may be regarded as both
beneficial and detrimental to plaque development. For example, inhibition of smooth muscle cell migration may reduce lesion size but
increase vulnerability to rupture. Glucocorticoids can have opposing effects dependent on species and type/duration of glucocorticoid
exposure. AngII—angiotensin II; EDRF—endothelium-derived relaxing factor; eNOS—endothelial nitric oxide synthase; ET-1—Endothelin-
1; ROS—reactive oxygen species; vSMC—vascular smooth muscle cell.
7. Mechanisms Controlling Glucocorticoid Bioavailability at the Vasculature
Intriguingly, the contrasting literature on glucocorticoid-mediated effects on macrophages
highlights both a crucial consideration in assessing conclusions drawn from past research, and
an important avenue of future research; namely, the effect of systemic glucocorticoids vs. local
glucocorticoid action. Glucocorticoid activity at the vascular wall is dependent not only on
the expression of its cognate receptor, but also on the bioavailability of the steroid itself and its
access to intracellular receptors. Consequently, numerous cell-specific mechanisms must be
considered when assessing the influence of glucocorticoids in atherosclerosis.
7.1. Pre-Receptor Metabolism of Glucocorticoids
The importance of local regulation of glucocorticoids at the vascular wall by the 11β-
hydroxysteroid dehydrogenase (11β-HSD) enzymes has been extensively reviewed [108–110].
Indeed, research over the past 20 years has demonstrated the importance of such pre-receptor
glucocorticoid metabolism by the 11β-HSD isozymes in mediating tissue-specific availabil-
ity of glucocorticoid. The 11β-HSD type 2 (11β-HSD2) isozyme catalyses the inactivation
of cortisol to cortisone (corticosterone to 11-dehydrocorticosterone in rodents), whereas
11β-HSD type 1 (11β-HSD1) catalyses the reverse reaction, activating cortisone to cortisol
(11-dehydrocorticosterone to corticosterone in rodents) [111]. Both enzymes are present in
the vasculature, with 11β-HSD1 mainly expressed in vSMCs in humans and rodents, and
11β-HSD2 is expressed mainly in endothelial cells [112,113]. This pre-receptor metabolism
controls downstream transcription, and so cell-specific expression of these metabolising
enzymes plays a key role in determining glucocorticoid action in these cells. Indeed, it is
hypothesised that 11β-HSD1 is heavily involved in vascular remodelling and angiogenesis,
whereas 11β-HSD2 protects against inappropriate glucocorticoid-mediated inhibition of va-
sodilation [114]. Evidence supporting a pathological role for 11β-HSD1 in atherosclerosis
is found in the increased expression of 11β-HSD1 in lipid-storing vSMCs within plaques
compared to “non-pathological” contractile vSMCs [115]. Moreover, 11β-HSD1 is increased
in aorta samples obtained during surgery from metabolic syndrome patients that have active
coronary atherosclerosis [116]. These changes indicate that increased local glucocorticoid
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action within the vasculature may be important in vascular remodelling and the development
of atherosclerosis.
Pre-clinical studies using genetic deletion and pharmacological inhibition of 11β-
HSD1 implicate this enzyme as a driver of atherosclerosis [67]. The inhibition of 11β-
HSD1 in ApoE−/− mice reduced neointimal thickening and increased collagen content,
promoting plaque stability [117]. In a similar model, 11β-HSD1 inhibition prevented
plaque progression and reduced aortic lesion size in parallel with an improved lipid
profile [118]. Two independently generated 11β-HSD1 knockout strains crossed with
ApoE−/− mice demonstrated similar protection from atherosclerosis [68,69]. In the study
by Kipari et al., 11β-HSD1 deficiency resulted in macrophages with increased cholesterol
ester export, implicating a role for glucocorticoids in increasing the cholesterol ester content
of macrophages and thus contributing to foam cell formation [69]. Intriguingly, this study
also demonstrated that 11β-HSD1 deficiency specifically in marrow-derived cells confers
atheroprotection, indicating the potential importance of 11β-HSD1 in macrophages and/or
related leukocytes. However, despite preclinical studies showing that 11β-HSD1 inhibition
is atheroprotective, no clinical studies of 11β-HSD1 inhibitors have been conducted for
the treatment of atherosclerosis [109]. This may be due to the lack efficacy of 11β-HSD1
inhibitors for the treatment of obesity and type 2 diabetes mellitus which has resulted in
them failing to progress beyond phase II clinical trials [119]. Thus, there remains an unmet
clinical need for identifying alternative mechanisms through which the body may control
glucocorticoid action in these cells.
7.2. Cognate Receptor Distribution and Regulation
The majority of glucocorticoid effects are a consequence of transcriptional actions
mediated through intracellular binding to either the low-affinity GR or the high-affinity
MR [7–9]. Upon ligand binding in the cytosolic space, the receptor–ligand complex dissoci-
ates from chaperone proteins and translocates to the nucleus, where it binds directly or
indirectly to the promoter region of target genes to either activate or repress transcription.
In contrast to the ubiquitous expression of GR, MR expression is limited to relatively few
tissues, with the kidney being the classical target for MR activation. Extra-renal MR has a
higher affinity for cortisol than aldosterone [8], and thus preventing aberrant MR activation
by glucocorticoids, which circulate at concentrations 100–1000 times higher than aldos-
terone, is dependent upon the co-expression of 11β-HSD2. Therefore, the response of cells
to glucocorticoids depends on the expression of both the receptors and pre-metabolising en-
zymes. For example, in the hippocampus and in adipose tissue, expression of both GR and
MR in the absence of 11β-HSD2 often results in inverted U-shaped relationships between
glucocorticoid concentrations and transcriptional outcomes as specific receptors become
activated and saturated [108,120]. In the vasculature, while GR and MR are expressed both
in endothelial cells and in vSMCs, GR levels are significantly greater in both cell types,
with the same being true in macrophages [67,108]. The expression of 11β-HSD2 both in
endothelial cells and in vSMCs suggests inactivation of glucocorticoids prevents signalling
via MR [67]. Indeed, the importance of this “roadblock” to MR activation was elegantly
demonstrated when ApoE−/− mice were crossed with 11β-HSD2−/− mice. These mice
exhibited increased development of severe atheromatous plaques even in that absence of
high-fat/Western diet, a mechanism attributed to glucocorticoid-mediated activation of
MR [67]. In a separate AAV-PCSK9 murine model of atherosclerosis, deletion of MR from
endothelial cells resulted in reduced plaque inflammation, attributed to downregulation of
endothelial cell adhesion molecule expression and thus reduced leukocyte infiltration [121].
Interestingly, this reduction in inflammation was only seen in male mice, not females,
suggesting a complex sex difference of the MR on atherosclerosis development in mice.
In contrast to endothelial MR activation appearing to promote atherosclerosis, evi-
dence indicates an athero-protective role for GR activation. Endothelial cell-specific GR
deletion results in more severe atherosclerosis and increased recruitment of macrophages
in an ApoE−/− model of atherosclerosis [122]. However, this athero-protective effect
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appears to be cell-specific, as activation of GR in macrophages has been shown to con-
tribute to atherogenesis. Macrophage-specific GR deletion in an LDLR−/− mouse model of
atherosclerosis did not alter lesion size or macrophage content [123]. Interestingly these
mice did display a reduction in vascular calcification in the lesion, implying a role for
GR-activation in macrophages in contributing to calcification in atherosclerosis. What
remains to be determined is a role for GR and/or MR dysregulation in mediating beneficial
or adverse glucocorticoid action with respect to atherosclerotic disease progression.
7.3. Control of Glucocorticoid Delivery to the Vasculature: A Role for CBG?
Under physiological conditions, CBG binds 80–90% of circulating glucocorticoids,
with 2–10% remaining unbound. Consequently, in line with the free hormone hypoth-
esis, this means that only between 2 and 10% of glucocorticoids are able to diffuse into
tissues and cells and exert biological activity. Recent genome-wide association studies
have demonstrated the importance of CBG in regulating circulating levels, with genetic
variation in the SERPINA6/1 locus influencing hepatic SERPINA6 expression associated
with morning plasma cortisol [35,124].
Unsurprisingly, given the role of glucocorticoids in numerous physiological settings,
CBG has been postulated to play a significant role in glucocorticoid action in several
pathological conditions. For example, in sepsis, a reduction in plasma CBG levels gives
rise to an increased free fraction of circulating cortisol in the circulation [125]; an important
anti-inflammatory response to enable the body to fight the systemic infection. Pre-clinical
studies with genetically modified mice have also indicated roles for CBG in the delivery of
glucocorticoids to tissue. CBG deficient mice are more vulnerable to LPS-induced sepsis,
and exhibit reduced glucocorticoid action in tissues such as liver and brain [126]. To our
knowledge, changes in CBG expression in atherosclerosis have yet to be evaluated in either
pre-clinical models or in humans. However, several factors known to regulate CBG levels
are altered in atherosclerosis. In particular, IL-6, which is elevated in early inflammation,
potentiates the inflammatory response and is implicated in lipid metabolism and plaque
formation [127], has been shown to inhibit CBG mRNA and protein expression in vitro.
Several studies have shown that increased plasma IL-6 is associated with a decrease in
CBG levels [128], with in vitro studies demonstrating that IL-6 inhibits CBG mRNA and
protein levels [129]. This implies that an IL-6-mediated reduction in CBG may allow more
“free” cortisol to act at the vasculature in atherosclerosis in an attempt to dampen the
inflammatory response. Yet, as discussed previously, prolonged rises in free cortisol may
become maladaptive and potentiate plaque development.
However, it is not only alterations in the levels of CBG which can influence gluco-
corticoid bioavailability. Structural changes in CBG protein are known to regulate its
affinity for glucocorticoids. In particular, proteolytic cleavage of the reactive certain loop
of CBG is known to result in an approximately 10-fold decrease in its binding affinity for
cortisol [130,131]. A small number of endogenous proteases are capable of this cleavage,
including NE and some MMPs, a mechanism that is thought to enable local release of
glucocorticoid at sites of inflammation [4]. NE action on CBG remains the most well
studied, and intriguingly, while NE action in atherosclerosis continues to be highlighted, a
link between NE-mediated cleavage of CBG and glucocorticoid delivery to the vasculature
during atherosclerosis remains to be investigated.
8. Conclusions
While it is clear that chronic, systemic glucocorticoid excess is positively associated
with increased atherosclerosis, evidence is now being uncovered for a causative role for
glucocorticoids in the cardiovascular complications arising from atherosclerotic plaque
formation. This has re-ignited the debate around the influence of glucocorticoids in disease
progression and treatment. The ability of glucocorticoids to affect multiple cell types
within the vasculature, in parallel with mediating opposing actions depending on the
concentration and cellular target, makes determination of relative importance difficult.
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The situation is made more complex by the multiple regulatory mechanisms still being
discovered that control glucocorticoid bioavailability, both at sites of plaque development
and in specific cells. Pre-clinical studies in genetically modified mice continue to aid
our understanding of these mechanisms, identifying potential new therapeutic targets to
control glucocorticoid action. However, it is clear that while these mechanisms can alter
glucocorticoid action, such changes need to be considered not only in the context of specific
cells, but in the context of plaque site, disease progression and treatment. For example,
limiting vSMC migration may be viewed as beneficial in limiting necrotic core formation,
but it may lead to a fibrous cap more vulnerable to rupture. Given the widespread use
of animal models, a greater understanding of the species-specific differences in plaque
composition and vulnerability would also be of significant benefit. Together with a better
knowledge of the mechanisms controlling local, endogenous glucocorticoid action, these
insights will be key in both predicting the response of patients to systemic glucocorticoid
treatment, and in advancing personalised, targeted glucocorticoid therapy to combat
cardiovascular disease.
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